Biotangents
Biotangents is closing one of animal health's most stubborn gaps: the protracted wait for diagnostic results. When a dairy cow shows signs of mastitis, farmers need answers within two hours for fast, precision treatment, not days later when the lab report arrives. For the vet, it removes guesswork, enabling early and accurate intervention.
AmpliSpec is our answer: a point-of-care molecular diagnostic platform delivering affordable, lab-quality pathogen identification on-farm within a single milking cycle.
Mastitis is our beachhead. It affects a third of UK cows annually at £250 to £300 per case, with a £20m UK market and over $500m global diagnostics opportunity. Working devices are deployed on UK farms, benchmarked against gold-standard PCR and culture. As global "test-before-treat" regulations shift from guidance to mandate, AmpliSpec is purpose-built for the new landscape.
Crucially, AmpliSpec is a platform: the same core chemistry runs in on-farm and laboratory formats today, with automated milking system integration a clear future opportunity. A Tier 1 global animal health company has signed as a paying customer for another major bovine disease, with applications across bovine, equine, and companion animals in scope.
Based near Edinburgh, Biotangents is backed by Kelvin Capital, Eos Advisory, and Scottish Enterprise.